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We aimed to study the role of coding VPS13C variants in a large cohort of patients with late-
onset Parkinson disease (PD) (LOPD).
Methods
VPS13C and its untranslated regions were sequenced using targeted next-generation se-
quencing in 1,567 patients with PD and 1,667 controls from 3 cohorts. Association tests of rare
potential homozygous and compound heterozygous variants and burden tests for rare het-
erozygous variants were performed. Common variants were analyzed using logistic regression
adjusted for age and sex in each of the cohorts, followed by a meta-analysis.
Results
No biallelic carriers of rare VPS13C variants were found among patients, and 2 carriers of
compound heterozygous variants were found in 2 controls. There was no statistically significant
burden of rare (minor allele frequency [MAF] <1%) or very rare (MAF <0.1%) codingVPS13C
variants in PD. A VPS13C haplotype including the p.R153H-p.I398I-p.I1132V-p.Q2376Q
variants was nominally associated with a reduced risk for PD (meta-analysis of the tagging SNP
p.I1132V [odds ratio = 0.48, 95% confidence interval = 0.28–0.82, p = 0.0052]). This haplotype
was not in linkage disequilibrium with the known genome-wide association study top hit.
Conclusions
Our results do not support a role for rare heterozygous or biallelic VPS13C variants in LOPD.
Additional genetic replication and functional studies are needed to examine the role of the
haplotype identified here associated with reduced risk for PD.
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The VPS13C gene is located within a risk locus for Parkinson
disease (PD), reported in large genome-wide association
studies (GWASs) of European population.1,2 The single nu-
cleotide polymorphism (SNP) reported in the GWAS
(rs2414739, chr15.hg19:g.61994134G>A) was also studied in
several Asian populations and in Iranians, with conflicting
results,3–7 possibly because of ethnicity-related differences.
Subsequently, homozygous and compound heterozygous
VPS13C mutations were identified as a rare cause of early
onset PD (EOPD) characterized by rapid progression and
early cognitive dysfunction. It was demonstrated that
VPS13C is partially localized at the mitochondrial mem-
brane, and its silencing led to mitochondrial dysfunction
and increased PINK1/Parkin-dependent mitophagy.8 A
follow-up study in 80 patients with EOPD identified an
additional patient with compound heterozygous mutations
with similar clinical features to the previously reported
patients.9 In another recent study, a homozygous deletion in
VPS13C was reported to be the probable cause of early
onset parkinsonism in 1 patient.10 Thus far, full sequencing
studies of VPS13C have not been reported in late-onset PD
(LOPD).
To further study the potential role of VPS13C variants in PD,
we sequenced its coding and regulatory regions using targeted
next-generation sequencing in 3 cohorts of PD (pre-
dominantly LOPD) and in controls. We examined the asso-
ciation of common, rare, and biallelic VPS13C variants on the
risk for PD. We further tested whether any coding variant or
variants in the untranslated regions of VPS13C are in linkage
disequilibrium (LD) with the top VPS13C-associated GWAS
hit to determine if any of these variants can explain the GWAS
association of this locus.
Methods
Study population
Three cohorts, with a total of 1,567 unrelated patients with
PD and 1,667 controls, were included in this study, detailed in
table 1. The first cohort was composed of French and French
Canadian participants recruited in Quebec (Canada) and in
France. This cohort was previously genotyped using the
GWAS OmniExpress array, the ethnicity was confirmed using
principal component analysis, and the samples that were of
different ethnicities were not included in this study. The
second cohort was recruited in New York—Columbia
University and was previously described.11 Most participants
from New York are of European descent and 38% are Ash-
kenazi Jewish (AJ), 40% of patients with PD, and 35% of
controls. This difference was not statistically significant, yet
we adjusted for ethnicity when analyzing this cohort to avoid
effects of ethnicity on the results. The third cohort was
recruited in Israel (Sheba Medical Center), and all partic-
ipants included in this study from the Israeli cohort are of full
AJ origin (all 4 grandparents are full AJ). All patients were
consecutively recruited through the clinics, and they represent
the typical LOPD patient population with age at onset (AAO)
of about 60 (table 1), as opposed to the studies published so
far on VPS13C in EOPD. As detailed below, because of the
differences in age and sex (table 1), statistical analysis was
adjusted and included age and sex as covariates. To account
for different ethnicities in the New York cohort, an ethnicity
covariate was also introduced in this cohort (GWAS data were
not available for this cohort; therefore, the reported ethnicity
was used and not principal components). All 3 cohorts were
sequenced in the same laboratory (McGill University), fol-
lowing the same protocol. All patients with PD were di-
agnosed by movement disorder specialists according to the
UK Brain Bank criteria,12 without excluding patients with
family history of PD, because it is now known that there are
familial cases of PD, so patients who reported family history of
PD were included. However, it is important to emphasize that
in the current study, only unrelated patients were included
and there were no multiple cases from the same family.
Standard protocol approvals, registrations,
and patient consents
The institutional review board (McGill University Health
Center Research Ethics Board—MUHC REB) approved the
study protocols (reference number IRB00010120). Informed
consent was obtained from all individual participants before
entering the study.
DNA extraction and VPS13C sequencing
DNA was extracted using a standard salting out protocol. The
coding sequence and regulatory regions of VPS13C were
targeted using molecular inversion probes (MIPs), which
were designed as previously described.13 MIPs were selected
based on their predicted coverage, quality, and overlap. All
MIPs used to sequence VPS13C in the present study are
included in table e-1, links.lww.com/NXG/A205. Targeted
DNA capture and amplification was performed as previously
described,14 and the full protocol is available on request. The
Glossary
AJ =Ashkenazi Jewish;ANOVA = analysis of variance;CADD =Combined AnnotationDependent Depletion;CI = confidence
interval; EOPD = early onset Parkinson disease; GATK = Genome Analysis Toolkit; GnomAD = Genome Aggregation
Database; GQ = quality score; GWAS = genome-wide association study; LD = linkage disequilibrium; LOPD = late onset
Parkinson disease;MAF =minor allele frequency;MIP = molecular inversion probe;OR = odds ratio; PD = Parkinson disease;
QC = quality control.
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library was sequenced using an Illumina HiSeq 2,500 platform
at the McGill University and Genome Quebec Innovation
Centre. Reads were mapped to the human reference genome
(hg19) with Burrows-Wheeler Aligner.15 Genome Analysis
Toolkit (v3.8) was used for postalignment quality control (QC)
and variant calling,16 and annotation variation was used for an-
notation.17 Data on the frequency of each VPS13C variant were
extracted from the public database Genome Aggregation Data-
base (GnomAD).18 Validation of the tagging variant p.I1132V
was performed using Sanger sequencing, with the following
primers: forward 59-CCGGGAAGGTAATGACAAAA-39 and
reverse 59-CCCCTGATTGAAAAGTCACA-39.
Quality control
During QC filtration using PLINK software v1.9,19 SNPs with
genotyping rate lower than 90% were excluded. Genotyping
rate cut-off for individuals was 90%, and individuals with
a lower genotyping rate were excluded. SNPs that deviated
from Hardy-Weinberg equilibrium set at p = 0.001 threshold
were filtered out. Threshold for missingness difference be-
tween cases and controls was set at p = 0.05 and the filtration
script adjusted it with Bonferroni correction. After these QC
steps, cohort composition was as described in table 1. To be
included in the analysis, minimum quality score (GQ) was set
to 30. Rare variants (minor allele frequency [MAF] <0.01 or
0.001) had to have a minimal coverage of >50× to be included,
and common variants had to have a minimal coverage of >15×
to be included in the analysis.
Statistical analysis
The association between common VPS13C variants and PD
was examined by using logistic regressionmodels using PLINK
v1.9, with the status (patient or control) as a dependent vari-
able, age and sex as covariates in all cohorts, and AJ ancestry as
an additional covariate in the New York cohort. To analyze rare
variants (MAF <0.01) and very rare variants (MAF <0.001), an
optimized sequence kernel association test (SKAT-O, R
package) was performed.20 In addition, we examined the bur-
den of predicted pathogenic variants using SKAT-O with
Combined Annotation Dependent Depletion (CADD) score
of ≥12.37 representing the top 2% of potentially deleterious
variants. The effects of SNP genotypes on the AAO was tested
using analysis of variance (ANOVA; in R software). Meta-
analysis of common variants in the 3 cohorts was performed
using metafor package in R software.21 LD in our data were
examined by PLINK v1.9 and LD between discovered SNPs
and the GWAS top hit rs2414739 was tested using LDlink
application, selecting all non-Finish Europeans.22
Data availability
Anonymized data are available on request by any qualified
investigator.
Results
Rare VPS13C variants and homozygous or
compound heterozygous VPS13C variants are
not associated with LOPD
The average coverage of VPS13C with the MIPs was 94% of
nucleotides covered at >10× and 90% covered at >50×. This
coverage, while not ideal, is better than the whole exome
sequencing coverage reported in the original study on
VPS13C in PD and better than the whole exome and whole
genome sequencing coverage of this specific gene in Gno-
mAD (gnomad.broadinstitute.org/). There were no differ-
ences in coverage between the cohorts and between patients
and controls. A total of 60 rare variants that are non-
synonymous, stop variants, or potentially affect a splicing site
were identified in the 3 cohorts and are detailed in table e-2,
links.lww.com/NXG/A206.
To examine whether rare homozygous or compound hetero-
zygous VPS13C variants may cause LOPD, and because
patients with VPS13C biallelic mutations are very rare, we in-
cluded only rare variants with allele frequency <0.001 in this
analysis. Only 2 carriers of 2 heterozygous variants were
identified, and both were controls (table e-3, links.lww.com/
NXG/A207), suggesting that biallelic mutations are not com-
mon in LOPD. Of note, we did not examine whether these 2
variants were on the same allele or different allele (compound
heterozygous) because they were found only in controls, which
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suggests that rare biallelic variants are not involved in LOPD in
our cohorts.
To further study a potential role for rare (allele frequency
<0.01) or very rare (allele frequency <0.001) VPS13C non-
synonymous or splice variants in LOPD, a SKAT-O was
performed on the variants detailed in table e-2, links.lww.
com/NXG/A206. In the French and French Canadian co-
hort, 33 (6.6%) patients with PD carried a rare variant com-
pared with 49 (6.2%) in controls. In the NY cohort, 43
patients with PD (8.6%) carried a rare variant compared with
29 (11.8%) in controls. In the Israeli cohort, 57 (11.9%)
patients with PD carried a rare variant compared with 59 (12.
1%) among controls. There was no association between rare
variants (French/French Canadian cohort p = 0.44, New York
cohort p = 0.34, and Israel cohort p = 0.91) or very rare
variants (French/French Canadian cohort p = 0.17, New York
cohort p = 0.85, and Israel cohort p = 0.89) and PD. We
further examined whether rare variants that are predicted to
be deleterious based on CADD score ≥12.37 are enriched in
PD (the variants included in this analysis are detailed in table
e-4, links.lww.com/NXG/A208), and no association was
found (French/French Canadian cohort p = 0.58, New York
cohort p = 0.39, and Israel cohort p = 0.40).
A VPS13C haplotype including the p.R153H-
p.I398I-p.I1132V-p.Q2376Q coding variants is
nominally associated with reduced risk for PD
Wehave identified 14 common coding variants in our cohort of
French and French Canadians and 13 such variants in each of
the NY and Israeli cohorts. More details on the number
of carriers and frequencies can be found in table e-5, links.lww.
com/NXG/A209. To test whether common coding variants in
VPS13C are associated with LOPD, logistic regression models
adjusted for age and sex were performed and additional ad-
justment for ethnicity was included in the New York cohort
(see methods). A nominal association was observed in 4 var-
iants (p.R153H [rs12595158, chr15.hg19:g.62316035C>T],
p.I398I [rs9635356, chr15.hg19:g.62299603T>G], p.I1132V
[rs3784635, chr15.hg19: g.62254989T>C], and p.Q2376Q
[rs17238189, chr15.hg19: g.62212781T>C]) with reduced risk
for PD in the New York cohort (table 2). These remained
nominally significant with and without including adjustment
for ethnicity, suggesting that ethnicity has no role in this














MAFa OR (95% CI)
p
Value
p.R153H rs12595158 c.G458A F/FC 15 27 0.0143 0.0157 0.0734 0.56
(0.26–1.20)
0.1358
NY 14 16 0.0135 0.0324 0.38
(0.17–0.84)
0.0172
Israel 16 22 0.0166 0.0225 0.0236 0.70
(0.19–2.6)
0.5940
p.I398I rs9635356 c.A1194C F/FC 15 28 0.0143 0.0163 0.0737 0.56
(0.26–1.20)
0.1330
NY 16 16 0.0154 0.0324 0.42
(0.20–0.91)
0.0274
Israel 15 19 0.0156 0.0195 0.0214 0.75
(0.19–2.89)
0.6752
p.I1132V rs3784635 c.A3394G F/FC 15 26 0.0143 0.0152 0.0726 0.69
(0.32–1.48)
0.3404
NY 11 18 0.0106 0.0363 0.28
(0.12–0.64)
0.0025
Israel 14 19 0.0145 0.0195 0.0233 0.65
(0.16–2.65)
0.5444
p.Q2376Q rs17238189 c.A7128G F/FC 10 24 0.0095 0.0140 0.0698 0.51
(0.21–1.23)
0.1344
NY 16 17 0.0154 0.0344 0.42
(0.20–0.90)
0.0245
Israel 16 20 0.0166 0.0215 0.0212 0.47
(0.07–3.10)
0.4350
Abbreviations: CI = confidence interval; F/FC = French/French Canadian; GnomAD = genome aggregation database; MAF = minor allele frequency; nt =
nucleotide; OR = odds ratio.
a GnomAD_ASJ frequencies were used for the Israeli cohort; all samples are Ashkenazi Jewish.
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association and only one of them, p. I1132V (odds ratio 0.28,
95% confidence interval 0.12–0.64, p = 0.0025), remained
statistically significant after correction for multiple compar-
isons. In the 2 other cohorts, these variants showed the same
directionality as in the New York cohort but did not reach
statistical significance (table 2). These 4 variants, p.R153H,
p.I398I, p.I1132V, and p.Q2376Q, are in strong or even
complete LD (table e-6, links.lww.com/NXG/A210). The
most significant tagging SNP of this haplotype, p. I1132V, was
validated using Sanger sequencing in all 3 cohorts. Meta-
analysis of all the common coding variants showed an associ-
ation of these 4 linked SNPs with reduced risk for PD (figure),
with similar directionality across all cohorts. To examine
whether this haplotype may affect AAO of PD, ANOVA with
the status of the p. I1132V variant was performed. This variant
was not associated with AAO in all 3 cohorts (French/French
Canadian cohort p = 0.65, NewYork cohort p = 0.34, and Israel
cohort p = 0.99).
None of these variants were in LDwith the known GWAS top
hit, rs2414739, and therefore, these associations do not ex-
plain the GWAS hit in the VPS13C locus. Of all the other
common coding variants, only one variant, p.E2008D
(rs78071599, chr15.hg19: g.62223303C>G), was in some LD
with the GWAS top hit (D’ = 0.808, r2 = 0.006, table e-7, links.
lww.com/NXG/A211), but this variant was not associated
with LOPD, and therefore, it also cannot explain the GWAS
hit in our populations. Of interest, an intronic variant,
rs78530361 (chr15.hg19: g.62214265C>T), was in LD with
the top GWAS SNP (D’ = 1, r2 = 0.003). Of note, r2 is low
since this intronic SNP has a much lower allele frequency than
the top GWAS hit, but every time the rs78530361 SNP is
found, it is on an allele which harbors the top GWAS hit
rs2414739. However, in our cohorts, this variant was not
associated with PD (p = 0.66), likely because of its very low r2
with the GWAS hit.
Discussion
Our study, which included full sequencing of VPS13C in 3
cohorts, identified 60 rare VPS13C variants (MAF <0.01) that
are nonsynonymous or affect splicing and 18 common var-
iants (MAF >0.01) in coding regions of the gene and splice
sites. Our results suggest that rare homozygous and com-
pound heterozygous variants are rare in LOPD and probably
have importance mainly in EOPD, as previously described.
We have identified a potentially protective haplotype, which
includes 4 variants, 2 of which are substitutions of amino
acids, p.R153H and p.I1132V. The association was mainly
driven by the NY cohort, but the 2 other cohorts demon-
strated similar directionality of effect and effect size and also
contributed to the association. It is unlikely that differences in
ethnicity in the NY cohort drove the association because
Figure Forest plots—meta-analyses of 4 VPS13C coding variants associated with reduced risk for PD
The forest plots depict the effects of the 4 VPS13C coding variants that create the haplotype associated with reduced PD risk in the 3 cohorts studied and their
meta-analyzed effect on risk for PD. The results in the randomeffectmodel are nearly identical. CI = confidence interval; FE = fixed effect; PD = Parkinson disease.
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analysis was with adjustment for ethnicity and analysis with-
out adjustment yielded nearly identical results, ruling out the
effect of ethnicity. The other 2 cohorts were of homogeneous
ethnicities; therefore, in these cohorts too, ethnicity could not
have affected the results. Of interest, this haplotype is not in
LD with the top GWAS SNP, rs2414739, suggesting that this
may be a secondary association in the VPS13C locus, which
was not identified in the previous studies. However, this
should be considered as preliminary results and needs to be
examined in additional cohorts to conclude whether this
haplotype is indeed associated with reduced risk for PD. Be-
cause the disease-causing mutations reported in VPS13C are
loss-of-function mutations, a protective effect could occur, for
example, because of the gain of function or overexpression. In
GTEx (gtexportal.org/home/), these variants were not as-
sociated with increased expression or affect splicing. The 2
nonsynonymous variants of this haplotype, p.R153H and p.
I1132V, have high CADD scores (22.8 and 13.7, re-
spectively), suggesting that they may affect the protein
structure or function. Whether there is such effect and
whether it is associated with gain-of-function mutation will
need to be examined in follow-up studies. Furthermore, the
full sequencing analysis did not identify any coding variant
that is in LD, with the original GWAS hit that can explain the
GWAS association in this locus. This may suggest that the
variant that has the main effect on the risk for PD in
the VPS13C is outside of the coding and untranslated regions
of the gene, likely being a regulatory element.
Previous studies on the top GWAS hit in the VPS13C locus
demonstrated conflicting results. Although significant asso-
ciations of the top GWAS hit in this locus (rs2414739) with
PD were found in Iranian5 and East Asian3 populations,
negative results were reported in Taiwanese4 and Han
Chinese6,7 populations. Therefore, it is possible that the as-
sociation of VPS13C with PD is population dependent. Of
note, the association in the current study was mainly driven by
populations enriched in Ashkenazi Jews, whereas in the
French/French Canadian cohort, the differences between
patients and controls were much smaller and not statistically
significant (table 2). This may suggest that this haplotype
association is population specific, and additional studies in
different populations are required to answer this question.
In our 3 cohorts, we did not find any very rare homozygous
variants with MAF <0.001 and found only 2 carriers of 2
heterozygous variants, both of which were controls (table e-3,
links.lww.com/NXG/A207). We were unable to determine if
the variants were in cis or trans, but because no carriers of 2
variants were found among patients, it is clear that VPS13C
biallelic mutations do not contribute to PD in our cohorts.
Previously reported cases of PD in carriers of compound
heterozygous or homozygous mutations, all shared a specific
clinical presentation of PD: early onset, rapid progression, and
early cognitive dysfunction.8,9 In 1 study, the patient’s AAO
was 39 and disease progression was moderately severe with
psychiatric symptoms and impaired cognition.9 In another
study, the 3 patients showed severe phenotypes: AAO of 25,
33, and 46 years, severe and early cognitive dysfunction, and
became bedridden at 31, 43, and 58 years, respectively.
Considering the young age of one of the compound hetero-
zygous VPS13C variant carriers in our cohort (30 years), it is
still possible although unlikely that this individual will develop
PD in the future. The negative results of the SKAT-O analyses
demonstrate that rare heterozygous variants in VPS13C do
not have an important role in PD in our cohorts.
Our study has several limitations. The differences between
patients with PD and controls in sex and mainly age are sig-
nificant in some of our cohorts. To address this limitation, we
included age and sex as covariates in the regression models.
Therefore, if the association of the protective haplotype was
related to age and not to disease status, we would likely not
observe an association in the adjusted model. Furthermore,
the association with the haplotype had the same directionality
and similar effect size in the NY cohort in which the controls
were older (and the association was statistically significant),
and in the other 2 cohorts, where the controls were younger,
likely ruling out the effect of age. There was no significant
difference in the percentage of Ashkenazi Jews between
patients and controls in the New York cohort, yet we still
performed the regression model with and without ethnicity as
a covariate, and in both analyses, the results remained sig-
nificant. Nevertheless, the fact that our populations are
enriched with relatively homogeneous populations such as
Ashkenazi Jews and French Canadians requires additional
studies in other populations. Another potential limitation is
that we could not analyze the effect of CNVs in VPS13C with
our data. Loss of function and exonic deletions/duplications
are rare in gnomAD, found in only 3 individuals at a hetero-
zygous state, and therefore not likely to have a major contri-
bution in PD. However, future studies to examine the
potential role of VPS13C in PD are required. Furthermore,
because no functional experiments were performed in the
current study, the potential effects of variants that we report
here should be examined in additional studies.
In conclusion, our results suggest that VPS13C variants have
a limited role in late-onset PD. The potentially PD protective
haplotype located within VPS13C, which requires additional
replications, may suggest that VPS13C could be a future target
for PD therapeutic development. If naturally occurring ge-
netic variants may reduce PD risk, it is conceivable that drugs
that can mimic their effects could be developed. Additional
genetic and functional studies will be required to determine if
VPS13C may be a viable target for PD drug development.
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